Regeneron Pharmaceuticals REGN Deferred revenue, net of current portion
Deferred revenue, net of current portion at other companies
Other financials
Where this comes from
Reported directly by Regeneron Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:ContractWithCustomerLiabilityNoncurrent.
The official record: Regeneron Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →
Ask your AI about Regeneron Pharmaceuticals's deferred revenue, net of current portion.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Regeneron Pharmaceuticals's deferred revenue, net of current portion?
- Regeneron Pharmaceuticals (REGN) reported deferred revenue, net of current portion of $225.1M in Q1 2026.
- How has Regeneron Pharmaceuticals's deferred revenue, net of current portion changed year-over-year?
- Regeneron Pharmaceuticals's deferred revenue, net of current portion increased by 6.3% year-over-year, from $211.8M to $225.1M.
- What is the long-term trend for Regeneron Pharmaceuticals's deferred revenue, net of current portion?
- Over 5 years (2020 to 2025), Regeneron Pharmaceuticals's deferred revenue, net of current portion has grown at a 29.3% compound annual growth rate (CAGR), from $57.8M to $208.7M.
- What does deferred revenue, net of current portion mean?
- This represents the portion of deferred revenue or contract liabilities that will be recognized as revenue beyond the next twelve months. It reflects long-term performance obligations under customer or collaboration contracts.